The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study

American Journal of Clinical Pathology

Volumn 141, Issue 5, 2014, Pages 630-638

  Dragomir, Anca ^a   De Wit, Meike ^b   Johansson, Christine ^c   Uhlen, Mathias ^d   Ponteń, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Cancer of unknown primary (CUP); Colorectal cancer; Cytokeratin 20; Immunohistochemistry; SATB2

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; ONCOPROTEIN; PROTEIN SATB2; TUMOR MARKER; UNCLASSIFIED DRUG; MATRIX ATTACHMENT REGION BINDING PROTEIN; SATB2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC COLORECTAL CANCER; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; AGED; CANCER OF UNKNOWN PRIMARY (CUP); COLORECTAL TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SATB2;

CANCER OF UNKNOWN PRIMARY (CUP); COLORECTAL CANCER; CYTOKERATIN 20; IMMUNOHISTOCHEMISTRY; SATB2;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-7; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902578953     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPWW2URZ9JKQJU     Document Type: Article

References (25)

1. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.
2. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-945.
3. Pontén F, Gry M, Fagerberg L, et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst Biol. 2009;5:337.
4. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
5. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002;38:758-763.
6. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.
7. Su MC, Yuan RH, Lin CY, et al. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol. 2008;21:1379-1386.
8. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35:937-948.
9. Wang S, Zhou J, Wang XY, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219:114-122.
10. Eberhard J, Gaber A, Wangefjord S, et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012;106:931-938.
11. Chung J, Lau J, Cheng LS, et al. SATB2 augments DeltaNp63alpha in head and neck squamous cell carcinoma. EMBO Rep. 2010;11:777-783.
12. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332-337.
13. Kampf C, Olsson I, Ryberg U, et al. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012;63(pii): 3620.
14. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
15. Hernandez BY, Frierson HF, Moskaluk CA, et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol. 2005;36:275-281.
16. Zhang PJ, Shah M, Spiegel GW, et al. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003;11:306-310.
17. Saad RS, Silverman JF, Khalifa MA, et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2009;17:196-201.
18. Bayrak R, Yenidunya S, Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011;207:156-160.
19. Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology. 1998;32:20-27.
20. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171-177.
21. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012;7:9.
22. Saad RS, Ghorab Z, Khalifa MA, et al. CDX2 as a marker for intestinal differentiation: its utility and limitations. World J Gastrointest Surg. 2011;3:159-166.
23. Tot T. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype. Med Sci Monit. 2004;10:BR139-143.
24. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
25. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27:141-149.